Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer

BACKGROUND: Hyperglycemia is recognized as a common adverse event for patients receiving alpelisib but has been little studied outside of clinical trials. We report the frequency of alpelisib-associated hyperglycemia in a real-world setting and evaluate proposed risk factors. PATIENTS AND METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Xuan, Behrendt, Carolyn E, Yost, Susan E, Patel, Niki, Samoa, Raynald, Stewart, Daphne, Sedrak, Mina, Lavasani, Sayeh, Waisman, James, Yuan, Yuan, Mortimer, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322119/
https://www.ncbi.nlm.nih.gov/pubmed/36943382
http://dx.doi.org/10.1093/oncolo/oyad024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322119/
https://www.ncbi.nlm.nih.gov/pubmed/36943382
http://dx.doi.org/10.1093/oncolo/oyad024

Ejemplares similares